Blue Note Therapeutics raises $26M to help treat cancer-related distress via cognitive behavioral stress management (CBSM)

By SharpBrains | March 9, 2021

Blue Note Ther­a­peu­tics Rais­es $26.25 Mil­lion in Series A Financ­ing (press release): Blue Note Ther­a­peu­tics, Inc., today announced the clos­ing of a Series A financ­ing round of $26.25 mil­lion. Pro­ceeds will allow the com­pa­ny to scale the orga­ni­za­tion and fund near-term clin­i­cal tri­als of its lead pre­scrip­tion dig­i­tal ther­a­peu­tic (PDT), which will poten­tial­ly improve the…

Read More

The FDA warns consumers not to use unapproved apps and devices to diagnose concussion

By SharpBrains | April 12, 2019

_______ FDA warns pub­lic not to use unap­proved or uncleared med­ical devices to help assess or diag­nose a con­cus­sion (news release): Today, the U.S. Food and Drug Admin­is­tra­tion is warn­ing the pub­lic not to use med­ical devices mar­ket­ed to con­sumers that claim to help assess, diag­nose or man­age head injury, includ­ing con­cus­sion, trau­mat­ic brain injury…

Read More

Explore the latest in cognitive remediation and addressing learning disabilities

By SharpBrains | January 11, 2017

Expo Day: Hap­py Neu­ron and Arrow­smith Pro­gram from Sharp­Brains Dur­ing Expo Day select­ed Sum­mit Part­ners and Spon­sors show­cased their lat­est ini­tia­tives and solu­tions. Franck Tarpin-Bernard, Man­ag­ing Direc­tor of Sci­en­tif­ic Brain Train­ing (SBT), dis­cussed new part­ner­ships fol­low­ing their ISO 13485 cer­ti­fi­ca­tion for med­ical devices — cog­ni­tive reme­di­a­tion. Jes­si­ca Poulin, Strate­gic Oper­a­tions Man­ag­er at the Arrow­smith Program,…

Read More